These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 32062041)

  • 21. Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1.
    Reinisch W; Bressler B; Curtis R; Parikh A; Yang H; Rosario M; Røseth A; Danese S; Feagan B; Sands BE; Ginsburg P; Dassopoulos T; Lewis J; Xu J; Wyant T
    Inflamm Bowel Dis; 2019 Mar; 25(4):803-810. PubMed ID: 30295811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis.
    Sandborn WJ; Colombel JF; Panaccione R; Dulai PS; Rosario M; Cao C; Barocas M; Lasch K
    J Crohns Colitis; 2019 Feb; 13(2):172-181. PubMed ID: 30285104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vedolizumab Dose Escalation Improves Therapeutic Response in a Subset of Patients with Ulcerative Colitis.
    Perry C; Fischer K; Elmoursi A; Kern C; Currier A; Kudaravalli P; Akanbi O; Tripathi N; Yarra P; Su L; Flomenhoft D; Stromberg A; Barrett TA
    Dig Dis Sci; 2021 Jun; 66(6):2051-2058. PubMed ID: 32710192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application of clinical decision support tools for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicentre study.
    Kim K; Park JJ; Yoon H; Lee J; Kim KO; Kim ES; Kim SY; Boo SJ; Jung Y; Yoo JH; Hwang SW; Park SH; Yang SK; Ye BD;
    Aliment Pharmacol Ther; 2024 Jun; 59(12):1539-1550. PubMed ID: 38616380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of Response to Vedolizumab in Patients with Ulcerative Colitis: Results from the Greek VEDO-IBD Cohort.
    Bamias G; Kokkotis G; Gizis M; Kapizioni C; Karmiris K; Koureta E; Kyriakos N; Leonidakis G; Makris K; Markopoulos P; Michalopoulos G; Michopoulos S; Papaconstantinou I; Polymeros D; Siakavellas SI; Triantafyllou K; Tsironi E; Tsoukali E; Tzouvala M; Viazis N; Xourafas V; Zacharopoulou E; Zampeli E; Zografos K; Papatheodoridis G; Mantzaris G
    Dig Dis Sci; 2022 Mar; 67(3):1007-1017. PubMed ID: 33751325
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
    Hu A; Kotze PG; Burgevin A; Tan W; Jess A; Li PS; Kroeker K; Halloran B; Panaccione R; Peyrin-Biroulet L; Ma C; Ananthakrishnan AN
    Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1366-1376.e2. PubMed ID: 32668338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting corticosteroid-free endoscopic remission with vedolizumab in ulcerative colitis.
    Waljee AK; Liu B; Sauder K; Zhu J; Govani SM; Stidham RW; Higgins PDR
    Aliment Pharmacol Ther; 2018 Mar; 47(6):763-772. PubMed ID: 29359519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis.
    Lukin D; Faleck D; Xu R; Zhang Y; Weiss A; Aniwan S; Kadire S; Tran G; Rahal M; Winters A; Chablaney S; Koliani-Pace JL; Meserve J; Campbell JP; Kochhar G; Bohm M; Varma S; Fischer M; Boland B; Singh S; Hirten R; Ungaro R; Lasch K; Shmidt E; Jairath V; Hudesman D; Chang S; Swaminath A; Shen B; Kane S; Loftus EV; Sands BE; Colombel JF; Siegel CA; Sandborn WJ; Dulai PS
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):126-135. PubMed ID: 33039584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study.
    Straatmijer T; Biemans VBC; Visschedijk M; Hoentjen F; de Vries A; van Bodegraven AA; Bodelier A; de Boer NKH; Dijkstra G; Festen N; Horjus C; Jansen JM; Jharap B; Mares W; van Schaik FDM; Ponsioen C; Romkens T; Srivastava N; van der Voorn MMPJA; West R; van der Woude J; Wolvers MDJ; Pierik M; van der Meulen-de Jong AE; Duijvestein M;
    Clin Gastroenterol Hepatol; 2023 Jan; 21(1):182-191.e2. PubMed ID: 35644343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.
    Narula N; Peerani F; Meserve J; Kochhar G; Chaudrey K; Hartke J; Chilukuri P; Koliani-Pace J; Winters A; Katta L; Shmidt E; Hirten R; Faleck D; Parikh MP; Whitehead D; Boland BS; Singh S; Sagi SV; Fischer M; Chang S; Barocas M; Luo M; Lasch K; Bohm M; Lukin D; Sultan K; Swaminath A; Hudesman D; Gupta N; Shen B; Kane S; Loftus EV; Siegel CA; Sands BE; Colombel JF; Sandborn WJ; Dulai PS
    Am J Gastroenterol; 2018 Sep; 113(9):1345. PubMed ID: 29946178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis.
    Narula N; Wong ECL; Marshall JK; Colombel JF; Dulai PS; Reinisch W
    Clin Gastroenterol Hepatol; 2022 Jul; 20(7):1588-1597.e3. PubMed ID: 34329776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and Validation of a Clinical Decision Support Tool That Incorporates Pharmacokinetic Data to Predict Endoscopic Healing in Patients Treated With Infliximab.
    Vande Casteele N; Jairath V; Jeyarajah J; Dulai PS; Singh S; Shackelton LM; Feagan BG; Sandborn WJ
    Clin Gastroenterol Hepatol; 2021 Jun; 19(6):1209-1217.e2. PubMed ID: 32376505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease.
    Schneider AM; Weghuber D; Hetzer B; Entenmann A; Müller T; Zimmermann G; Schütz S; Huber WD; Pichler J
    BMC Gastroenterol; 2018 Sep; 18(1):140. PubMed ID: 30219028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exposure-efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn's disease and ulcerative colitis.
    D'Haens G; Rosario M; Polhamus D; Dirks NL; Chen C; Kisfalvi K; Agboton C; Vermeire S; Feagan BG; Sandborn WJ
    Expert Rev Clin Pharmacol; 2024 Apr; 17(4):403-412. PubMed ID: 38441048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.
    Singh N; Rabizadeh S; Jossen J; Pittman N; Check M; Hashemi G; Phan BL; Hyams JS; Dubinsky MC
    Inflamm Bowel Dis; 2016 Sep; 22(9):2121-6. PubMed ID: 27542130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparing the efficacy of vedolizumab between males and females: a post-hoc analysis of GEMINI-1 and VARSITY.
    Chhibba T; Wong ECL; Reinisch W; Targownik L; Narula N
    Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):704-711. PubMed ID: 38526945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Vedolizumab in patients with inflammatory bowel diseases of in real clinical practice].
    Shapina MV; Nanaeva BA
    Ter Arkh; 2020 Apr; 92(2):67-73. PubMed ID: 32598721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Confocal laser endomicroscopy as predictive biomarker of clinical and endoscopic efficacy of vedolizumab in ulcerative colitis: The DETECT study.
    Quénéhervé L; Trang-Poisson C; Fantou A; Flamant M; Durand T; Bouguen G; Bregeon J; Oullier T; Amil M; Dewitte M; Bardot S; Blandin S; Braudeau C; Vibet MA; Josien R; Neunlist M; Bourreille A
    PLoS One; 2024; 19(4):e0298313. PubMed ID: 38564601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO)
    Ylisaukko-Oja T; Aaltonen J; Nuutinen H; Blomster T; Jussila A; Pajala M; Salminen K; Moilanen V; Hakala K; Kellokumpu M; Toljamo K; Rautiainen H; Kuisma J; Peräaho M; Molander P; Silvennoinen J; Liukkonen V; Henricson H; Tillonen J; Esterinen M; Nielsen C; Hirsi E; Lääne M; Suhonen UM; Vihriälä I; Mäkelä P; Puhto M; Punkkinen J; Sulonen H; Herrala S; Jokelainen J; Tamminen K; Sipponen T
    Scand J Gastroenterol; 2018 Feb; 53(2):158-167. PubMed ID: 29258369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials.
    Feagan BG; Sandborn WJ; Colombel JF; Byrne SO; Khalid JM; Kempf C; Geransar P; Bhayat F; Rubin DT
    J Crohns Colitis; 2019 Jan; 13(1):50-57. PubMed ID: 30203005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.